Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 5/20 | 0.62 |
| ▸ | CTSB | P07858 | 4/20 | 0.62 |
| ▸ | ADAM17 | P78536 | 7/20 | 0.58 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3915375 | 0.88 | CAPN1 (0.64) | CAPN1CTSBADAM17LARS1MMP1 | |
| SCHEMBL3906292 | 0.87 | ADAM17 (0.48) | CAPN1CTSBADAM17F2SLC1A3 | |
| SCHEMBL3904676 | 0.80 | CTSL (0.54) | MMP1F2SMN1; SMN2 | |
| SCHEMBL1770561 | 0.79 | ADAM17 (0.60) | ADAM17LARS1MMP1F2SLC1A3 | |
| SCHEMBL1770556 | 0.79 | ADAM17 (0.60) | ADAM17LARS1MMP1F2SLC1A3 | |
| SCHEMBL14345720 | 0.76 | CAPN1 (1.00) | CAPN1CTSBADAM17LARS1MMP1 | |
| SCHEMBL6979815 | 0.76 | SLC1A3 (0.60) | ADAM17LARS1F2SLC1A3SLC1A2 | |
| SCHEMBL6985255 | 0.76 | ADAM17 (0.49) | ADAM17LARS1F2SLC1A3SLC1A2 | |
| SCHEMBL3907752 | 0.76 | CAPN1 (0.49) | CAPN1CTSBADAM17LARS1MMP1 | |
| SCHEMBL3912360 | 0.74 | CAPN1 (0.55) | CAPN1CTSBADAM17LARS1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572833-B2 | Drug composition comprising dipeptidyl aldehyde derivative | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-11 | — | — | US | disclosed |
| US-7052714-B1 | Ophthalmic adhesive preparations for percutaneous adsorption | SENJU PHARMACEUTICAL CO., LTD (JP) | 2006-05-30 | — | — | US | disclosed |
| US-20040048929-A1 | Drug composition comprising dipeptidyl aldehyde derivative | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1334718-A1 | DRUG COMPOSITION COMPRISING DIPEPTYDYL ALDEHYDE DERIVATIVE | Senju Pharmaceutical Co., Ltd. (JP) | 2003-08-13 | — | — | EP | disclosed |
| EP-0927716-B1 | Angiogenesis inhibitor | SENJU PHARMA CO (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6551999-B1 | For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| EP-0771565-B1 | Angiogenesis inhibitor | SENJU PHARMA CO (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-1221315-A1 | OPHTHALMIC ADHESIVE PREPARATIONS FOR PERCUTANEOUS ABSORPTION | Senju Pharmaceutical Co., Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| US-6214800-B1 | ANGIOGENESIS INHIBITORS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2001-04-10 | — | — | US | disclosed |
| US-6057290-A | ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2000-05-02 | — | — | US | disclosed |
| EP-0928786-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-14 | — | — | EP | disclosed |
| EP-0927716-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-07 | — | — | EP | disclosed |
| EP-0771565-A2 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048929-A1 | Drug composition comprising dipeptidyl aldehyde derivative | DPP4, DPP3, DPP7 | CAPN1 2707/4885CTSB 1998/4885ADAM17 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.